Sublingual and subcutaneous immunotherapy are both proven to be effective ways to target the source of allergies. Studies have shown the sublingual method to have a lower risk for anaphylaxis, allowing it to be administered from home. As a result, sublingual immunotherapy can save patients time, as well as potentially hundreds of dollars in co-pays.
Huang Y, Wang C, Wang X, et al. Efficacy and safety of subcutaneous immunotherapy with house dust mite for allergic rhinitis: A meta-analysis of randomized controlled trials. Allergy 2019;74(1):189-92. https://pubmed.ncbi.nlm.nih.gov/30074245/
Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy 2017;72(11):1597-631. https://onlinelibrary.wiley.com/doi/full/10.1111/all.13201
Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clin Transl Allergy 2017;7:24.
André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol. 2000 Mar;121(3):229-34. doi: 10.1159/000024322. PMID: 10729782. https://pubmed.ncbi.nlm.nih.gov/10729782/